The difference of anticancer immune response observed in patients has been attributed to a variety of reasons, such as expression levels of PD-L1 and PD-1, genetic mutations of cancer cells, as well as development of neo-antigens 7, and represents a grand challenge to cancer immunotherapy. This evidence concerns the gene CD274 and cancer.